Polyheme or any other "blood substitute" (actually oxygen carrier) will be very expensive until a generic is available. Recombinant EPO made Amgen and Ortho Biotech rich. Now Amgen fights companies who are trying to develop a similar product. They are fighting to protect their profits.

__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email